Drug intelligence / Profile preview

acitretin + etretinate

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Acitretin and etretinate are synthetic retinoids used primarily for treating severe psoriasis. Etretinate is the ethylester form of acitretin, while acitretin is the active metabolite of etretinate with a shorter half-life. Both drugs work by normalizing keratinocyte differentiation and reducing inflammation. Etretinate was withdrawn from the market due to its long half-life and teratogenic effects, while acitretin replaced it as the preferred treatment. Both drugs are highly teratogenic, requiring strict contraception measures. Acitretin can be converted back to etretinate when combined with alcohol.

Targets

RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on acitretin + etretinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acitretin + etretinate.

Explore the full profile